Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| AlloVir Inc | ALVR | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.7549 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.7549 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.58 - 6.12 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.7549 | USD |
AlloVir Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 85.55M | 114.06M | - | 0 | -190.42M | -1.67 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
AlloVir News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALVR Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.75 | 0.7899 | 0.731 | 0.7459831 | 265,349 | 0.0049 | 0.65% |
| 1 Month | 0.781 | 0.82 | 0.58 | 0.7604739 | 327,522 | -0.0261 | -3.34% |
| 3 Months | 0.711 | 0.85 | 0.58 | 0.7649512 | 442,358 | 0.0439 | 6.17% |
| 6 Months | 1.97 | 2.485 | 0.58 | 0.8372693 | 1,287,945 | -1.22 | -61.68% |
| 1 Year | 3.96 | 6.12 | 0.58 | 1.59 | 1,077,389 | -3.21 | -80.94% |
| 3 Years | 22.87 | 26.41 | 0.58 | 4.66 | 677,353 | -22.12 | -96.70% |
| 5 Years | 22.82 | 48.96 | 0.58 | 7.81 | 600,626 | -22.07 | -96.69% |
AlloVir Description
| AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. |
